for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ビジネス

CureVac fails in pivotal COVID-19 vaccine trial

German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union. Emer McCarthy reports.

最新のビデオ
エンタテインメント
世界のこぼれ話
スポーツ
テクノロジー

ビジネス

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up